Researchers Share New Approach to Advancing Treatment of Cancers of the Bile Ducts, Gallbladder and Liver; Canliv Foundation to Link Genomics to Clinical Trials

Share Article

Cancers of the liver are increasing in incidence faster than any other cancer in the U.S. and other western countries, and are a leading cause of cancer death worldwide. CanLiv - The Hepatobiliary Cancers Foundation will bring together researchers, cancer doctors, patient advocates, and industry partners to collaboratively develop better treatment for liver cancer patients at its 4th Annual Research Symposium, May 9, 2014 at ASCO Conference Center in Alexandria, VA.

Cross disciplinary scientific research that seeks practical applications that help people will be the focus of Linking Genomics to Clinical Trials. “Since our founding in 2007, CanLiv has made extraordinary strides in connecting key researchers with one another, and focusing their work on these little-understood cancers,” according to Dr. Melanie Thomas, President of CanLiv and Associate Director of Clinical Investigations at Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, March 31, 2014.

Translational science – cross-disciplinary scientific research that seeks practical applications that help people – will be the focus of the second CanLiv Foundation ( symposium. Scores of researchers, cancer doctors, patient advocates, foundation experts and others are expected to gather May 9, 2014 in Alexandria, VA to share insight on the causes and treatments of “orphan” cancers of the gallbladder and bile ducts.

With the focus now is on breaking down barriers, sharing discoveries and supporting one another across disciplines and across time zones the 4th Annual CanLiv Research Symposium will be opened with an inspirational address by Melanie Thomas, MD, Hollings Cancer Center, President, CanLiv. Speaking at the symposium will be Lewis Roberts, MB, CHB, PhD, Mayo Clinic, and CanLiv Board member reporting on the Status of Liver Registry and CanLiv Consortium who then will moderate international session discussing breakthroughs in Genetics and Genomics of GB and Cholangiocarcinoma. He will be joined by Laura Wood, MD, PhD, Assistant Professor of Pathology, Johns Hopkins School of Medicine, Jesper B. Andersen, PhD, NCI Laboratory for Experimental Carcinogenesis; Andersen Group at Biotech, Research and Innovation Centre (BRIC), University of Copenhagen, and Roongruedee Chaiteerakij, MD, Center for Clinical and Translations Science, Mayo Clinic.. The afternoon session will see Anthony El-Khoueiry, USC/Norris Cancer Center moderate Philip Johnson, MD, Professor in Translational Oncology, University of Liverpool, UK, R. Kate (Katie) Kelley, MD, Assistant Professor, Department of Medicine, UCSF, and Florin Selaru, MD, Assistant Professor of Medicine, Johns Hopkins. Diagnostics for Gallbladder Carcinoma news will be shared by expert Peter Shamanian, MD from Montefiore Hospital together withBenjamin R. Kipp, PhD, and John B. Kisiel, MD, both from Mayo Clinic. The highlight to cap off the day will be Strategic Initiatives to Involve Patients in the Research Process Discussion lead by Melanie Thomas, MD and Donna Cryer, JD, CEO Cryer Health. There will also be a scientific poster presentation and industry showcase to engage the think tank of international cancer researchers.

About CanLiv:

The CanLiv Foundation was created by a group of cancer researchers on several continents who were all struck by the absence of knowledge and shared insights related to hepatobiliary cancers (liver, gallbladder and bile ducts). Since 2007, they have innovated a program of research and information sharing, created a patient-focused website with educational materials and more, and shined a light on cancers that affect millions of patients worldwide. To find our patient resources or donate to the cause please visit


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website